RxDoctor Payments DataLook up a doctor →

Jeffrey Goldstein, MD

Interventional Cardiology · Bloomington, ILNPI 1689756900

Payments from drug & device makers

$294,361in general payments, 2019–2025

Across 359 payments — averaging $819.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$125K
  • Boston Scientific$76K
  • Bard Peripheral Vascular, Inc.$42K
  • Edwards Lifesciences$18K
  • Surmodics, Inc.$16K
  • Medtronic$7K
  • plus $10K from 19 others
$1,500in research payments, 2019–2025

Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$2K

What the payments were for

  • Speaking & faculty fees$5,81361%
  • Food & beverage$3,74639%
  • Gifts$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$294,361 in reported general payments places this provider in the 90th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$415,891
Medicare patients
1,864
Services billed
3,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$279,400
EntrestoSacubitril/Valsartan262$254,751
BrilintaTicagrelor64$61,331
XareltoRivaroxaban45$48,730
Repatha SureclickEvolocumab22$26,552
Praluent PenAlirocumab23$16,057
FarxigaDapagliflozin Propanediol12$12,179
Metoprolol Succinate528$6,596
ClopidogrelClopidogrel Bisulfate599$5,547
Atorvastatin Calcium358$3,363
Potassium Chloride122$2,997
Digoxin60$1,688
Metolazone47$1,647
Losartan Potassium205$1,639
Ranolazine ErRanolazine16$1,626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$279,400268 claims
NovartisEntresto$56$254,751262 claims
AstraZenecaBrilinta, Farxiga$60$73,51076 claims
Johnson & JohnsonXarelto$76$48,73045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Bloomington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →